Introduction:
British companies Arecor Therapeutics plc and TRx Biosciences Ltd are collaborating to develop an oral GLP-1 receptor agonist with enhanced bioavailability. Obesity drugs currently dominate the $80 billion market, with Novo Nordisk’s injected semaglutide and Eli Lilly’s tirzepatide leading the way. However, the oral delivery of GLP-1 receptor agonists is challenging due to low bioavailability. Arecor and TRx plan to use their respective technologies to create an oral formulation that will be more convenient for patients to use.
- The collaboration aims to develop an oral GLP-1 receptor agonist with enhanced bioavailability for the obesity drug market.
- Oral delivery of GLP-1 receptor agonists is challenging due to the low bioavailability caused by the digestive system’s proteolytic nature.
- TRx Biosciences will use its LipiCore™ oral delivery technology and Arecor’s formulation platform, Arestat™, to develop the oral GLP-1 receptor agonist.
- There is potential for the collaboration to expand beyond the GLP-1 agonist program to develop additional peptide products targeting obesity-related health conditions and other therapeutic areas.
- The financial details of the collaboration have not been disclosed.
Conclusion:
Arecor Therapeutics and TRx Biosciences are partnering to develop an oral GLP-1 receptor agonist with enhanced bioavailability for the obesity drug market. The collaboration aims to overcome the challenges of low bioavailability associated with oral delivery of GLP-1 receptor agonists, which could provide more convenient treatment options for patients. The partnership also opens up opportunities to develop other peptide products targeting obesity-related health conditions and other therapeutic areas.
